The Art of the Quadpill: A New Strategy for Blood Pressure Control<\/p>\n
Key Points:<\/p>\n
\u2022\u2060 \u2060Hypertension management is shifting toward early multidrug therapy and single-pill strategies to improve BP control and adherence.<\/p>\n
\u2022\u2060 \u2060Triple single-pill therapy (telmisartan + amlodipine + indapamide) showed 70% BP control vs 37% with placebo in a phase 3 trial.<\/p>\n
(Note: Amlodipine may cause lower limb edema, dose-related; combining with ACE inhibitors or ARBs can reduce edema by ~38%, along with leg elevation or compression stockings.)<\/p>\n
\u2022\u2060 \u2060Quadpill strategy (ultra-low quarter1\/4-recommended dose combination of four antihypertensive drugs) showed greater BP reduction than standard monotherapy in the QUARTET trial.<\/p>\n
\u2022\u2060 \u2060Quadpill strategy (ultra-low quarter-dose combination):
\n\u2013 Irbesartan 37.5 mg
\n\u2013 Amlodipine 1.25 mg
\n\u2013 Indapamide 0.625 mg
\n\u2013 Bisoprolol 2.5 mg<\/p>\n
\u2022\u2060 \u2060Compared with standard monotherapy (Irbesartan 150 mg) in the QUARTET trial , the quadpill achieved greater BP reduction and better control rates.<\/p>\n
\u2022\u2060 \u2060New therapies for resistant hypertension include:
\n\u2013 Baxdrostat (aldosterone synthase inhibitor)
\n\u2013 Aprocitentan (endothelin receptor antagonist).<\/p>\n
\u2022\u2060 \u2060BaxHTN phase 3 trial (796 patients): SBP reduction \u22489\u201310 mmHg vs placebo.<\/p>\n
\u2022\u2060 \u2060Additional cardiometabolic agents such as SGLT2 inhibitors and GLP-1 agonists also contribute to BP reduction.<\/p>\n
Source
\nMedscape \u2013
\nFebruary 13, 2026<\/p>\n